N/A N=24 The Effects of Respiratory Training on Voice
Muscle Tension Dysphonia
Primary: Post Training Lung Volume Initiation — 21.07; 27.04 % vital capacity relative to rest level — p=<0.0005
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=6 Thalamic Deep Brain Stimulation for Spasmodic Dysphonia- DEBUSSY Trial
Spasmodic Dysphonia · Laryngeal Dystonia · Deep Brain Stimulation
Primary: Unified Spasmodic Dysphonia Rating Scale (USDRS) — 2.5; 3.75 units on a scale — p=0.025
N/A N=20 rTMS in Spasmodic Dysphonia
Spasmodic Dysphonia · Laryngeal Dystonia
Primary: Adverse Response to rTMS — 0; 0 Participants
N/A N=30 Evaluating the Feasibility of Acapella® Choice as a Dysphonia Treatment
Muscle Tension Dysphonia · Vocal Fold Palsy · Vocal Cord Paralysis
Primary: Change in Baseline Cepstral/Spectral Index of Dysphonia (CSID) — 1.22; 4.45; 4.56; 3.13 score on a scale
Phase 2 N=22 DaxibotulinumtoxinA Injection for Treatment of Adductor Spasmodic Dysphonia
Adductor Spasmodic Dysphonia · Voice Disorders · Spasmodic Dysphonia
Primary: Our Primary Outcome is the Difference in VHI-10 Score at 30 Days After Injection With DAXI. — 17.81 units on a scale — p=<0.001
N/A N=42 Laryngeal Vibration for Spasmodic Dysphonia
Spasmodic Dysphonia
Primary: Voice Assessment During First Visit — 0.045; 0.17; 0.13; -0.47 decibel
N/A N=435 Application of Ideal Binary Masking to Disordered Speech
Hearing Loss, Sensorineural · Dysarthria
Primary: Percent Correct Speech Intelligibility — 69; 63 percentage of words correctly reported
Phase 3 N=108 Sodium Oxybate in Spasmodic Dysphonia and Voice Tremor
Spasmodic Dysphonia · Voice Tremor
Primary: Symptom Severity — 28.0; 18.6; 14.2; 12.3 score on a scale — p=0.01
Phase 2 N=21 Controlled Study to Evaluate the Safety and Efficacy of Azficel-T for Vocal Fold Scarring and Age-Related Dysphonia
Dysphonia Resulting From Vocal Fold Scarring · Age-related Dysphonia
Primary: Number of Participants With Any Improvement From Baseline in Mucosal Wave Grade — 14; 5 Participants
Phase 3 N=32 Spasmodic Dysphonia Pain
Spasmodic Dysphonia
Primary: Pain Experienced — 2; 2; 2 score on a scale
N/A N=20 Respiratory Muscle Strength Training in Presbyphonia
Presbylarynx
Primary: Post-Treatment Mean in Voice Handicap Index Score — 15.00; 15.75; 18.50 score on a scale — p=0.041
Phase 2 N=53 Voice Tremor in Spasmodic Dysphonia: Central Mechanisms and Treatment Response
Spasmodic Dysphonia · Voice Tremor
Primary: Number of Participants Who Reported Positive Effects. — 17; 20 Participants
N/A N=13 Assessment of Laryngopharyngeal Sensation in Adductor Spasmodic Dysphonia
Spasmodic Dysphonia · Adductor Spasmodic Dysphonia · Voice Disorders
Primary: Laryngeal Adductor Reflex — 13 Participants
N/A N=30 MyoVoice to Restore Natural, Hands-free Communication to Individuals With Vocal Impairments
Rehabilitation of Speech and Language Disorders · Speech Disorders · Speech, Alaryngeal
Primary: Pitch Recognition Accuracy — 7.70 Percent agreement to reference pitch
N/A N=31 Controlled Phonation and Vocal Rest Programs After Acute Vocal Exertion in Healthy Adults
Healthy
Primary: Phonation Threshold Pressure — 5.41; 5.08; 6.39; 6.33 cmH20 — p=<0.001
N/A N=215 Perceptual Training to Improve Listeners' Ability to Understand Speech Produced by Individuals With Dysarthria
Dysarthria · Intelligibility, Speech
Primary: Pretest Transcription Accuracy — 77.8; 35.3; 52.9; 30 percentage of words correct
N/A N=55 Phonatory Movement of the Pharyngoesophageal Mucosa in Laryngectomy Patients
Larynx Cancer · Laryngectomy; Status
Primary: High Speed Video Endoscopy Recordings — 53; 2; 2; 38 Participants
N/A N=40 Physiological Flow of Liquids Used in Dysphagia Management (Neuro)
Amyotrophic Lateral Sclerosis · Parkinson Disease · Dysphagia
Primary: Number of Participants With Residue of Concern (Observational) — 6; 6; 3; 6 Participants
N/A N=154 Oropharyngeal Dysphagia in Patients With Community Acquired Pneumonia
Dysphagia · Pneumonia
Primary: Intra Hospital Mortality — 7; 0 Participants
N/A N=58 Voice Therapy With a Semi-occluded Vocal Tract
Voice Disorders
Primary: (Supra)Glottic Activity: Amplitude of Vibration — 37.7; 32.5; 28.8; 37.1 percentage
N/A N=36 Voice Treatment for Parkinson's Disease
Idiopathic Parkinson Disease
Primary: Treatment-related Changes in Vocal Intensity Will be Assessed Using Acoustic Analysis. — 3; 3; 0.26 Decibels
N/A N=34 DESIPHER_Speech Degradation as an Indicator of Physiological Degeneration in ALS
Amyotrophic Lateral Sclerosis
Primary: Change in Percent of Expected Lung Force Vital Capacity — -1.25 % Expected Forced Vital Capacity
Phase 4 N=78 Dysphagia Following Anterior Cervical Spine Surgery; Single Dose Steroid vs Saline (DysDexVSSal)
Dysphagia
Primary: Change in the Occurrence of Dysphagia -Bazaz Scale — 2.17; 3.27 score on a scale
N/A N=109 Mechanisms and Management of Infant Dysphagia
Dysphagia · Airway Aspiration · Airway Penetration
Primary: Number of Participants With Successful Safe Oral Feeding — 51; 31 Participants — p=0.008
N/A N=30 Effect of Semi-occluded Vocal Tract Therapy on the Phonation of Children With Vocal Fold Nodules
Voice Disorders in Children · Vocal Nodules in Children · Hoarseness
Primary: Change in Dysphonia Severity Index — 1.8; 1.8; 0.0 units on a scale — p=0.024